We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$697M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+11.78%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$291M
AUM Growth
+$111M
(+61%)
Cap. Flow
+$101M
Cap. Flow
% of AUM
34.52%
Top 10 Holdings %
Top 10 Hldgs %
41.32%
Holding
85
New
36
Increased
17
Reduced
10
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$14.8M |
| 2 |
Bionano Genomics
BNGO
|
+$10.2M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$7.48M |
| 4 |
UROV
Urovant Sciences Ltd.
UROV
|
+$6.99M |
| 5 |
Biogen
BIIB
|
+$6.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$5.97M |
| 2 |
Elevance Health
ELV
|
+$4.88M |
| 3 |
Icon
ICLR
|
+$4.61M |
| 4 |
Willis Towers Watson
WTW
|
+$3.94M |
| 5 |
Revvity
RVTY
|
+$3.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.76% |
| 2 | Financials | 4.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Axsome Therapeutics
AXSM
$11.2B
| $1.44M | 0.49% |
416,458
+223,168
| +115% | +$661K |
|
52
electroCore
ECOR
$54.8M
| $1.21M | 0.41% |
5,747
-8,494
| -60% | -$1.87M |
|
|
SPPI
53
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $1.19M | 0.41% |
70,712
-72,838
| -51% | -$1.58M |
|
|
PFNX
54
DELISTED
Pfenex Inc.
PFNX
| $1.09M | 0.37% |
213,608
+24,089
| +13% | +$124K |
|
55
Establishment Labs
ESTA
$2.72B
| $1.08M | 0.37% |
+44,678
| New | +$1.15M |
|
56
Abbott
ABT
$183B
| $1.04M | 0.36% |
+14,220
| New | +$934K |
|
|
TMDI
57
DELISTED
Titan Medical Inc. Ordinary Shares
TMDI
| $949K | 0.33% |
+445,680
| New | +$1.26M |
|
58
Achieve Life Sciences
ACHV
$659M
| $523K | 0.18% |
+8,299
| New | +$525K |
|
|
OPTN
59
DELISTED
OptiNose
OPTN
| $336K | 0.12% |
+1,805
| New | +$515K |
|
60
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
| $230K | 0.08% |
+21,600
| New | +$248K |
|
|
ONCT
61
PUT
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $81K | 0.03% |
+368
| New | +$883K |
|
62
PUT
Immunic
IMUX
$190M
| $54K | 0.02% |
487
+452
| +1,291% | +$1.18M |
|
|
63
Immunic
IMUX
$190M
| $29K | 0.01% |
+259
| New | +$676K |
|
64
Actinium Pharmaceuticals
ATNM
$26.3M
| – | – |
-29,080
| Closed | -$558K |
|
|
65
Boston Scientific
BSX
$69.5B
| – | – |
-182,633
| Closed | -$5.97M |
|
66
Cencora
COR
$60.6B
| – | – |
-13,840
| Closed | -$1.18M |
|
67
PUT
Deutsche Bank
DB
$69B
| – | – |
-654,800
| Closed | -$6.95M |
|
68
Incyte
INCY
$24.2B
| – | – |
-42,000
| Closed | -$2.81M |
|
69
McKesson
MCK
$100B
| – | – |
-17,500
| Closed | -$2.33M |
|
70
Ocugen
OCGN
$416M
| – | – |
-653
| Closed | -$98K |
|
|
ACH
71
Accendra Health
ACH
$237M
| – | – |
-75,000
| Closed | -$1.25M |
|
|
PINC
72
PUT
DELISTED
Premier
PINC
| – | – |
-40,000
| Closed | -$1.46M |
|
|
73
Revvity
RVTY
$12.6B
| – | – |
-52,620
| Closed | -$3.85M |
|
74
CALL
Viatris
VTRS
$20.4B
| – | – |
-100,000
| Closed | -$3.61M |
|
75
PUT
West Pharmaceutical
WST
$24B
| – | – |
-14,100
| Closed | -$1.4M |
|
Similar funds
GUB
KLI
JA
WIC
AAM
TCM
CA
SAM
Sio Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Sio Capital Management held 85 positions worth $291M, up 61% from $181M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Sio Capital Management deployed $101M of net new capital in Q3 2018, opening 36 new positions and adding to 17 existing holdings. Its largest new stake was GSK: 291,168 shares worth $14.6M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 80% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Elevance Health, an estimated $4.88M trimmed.
- Sio Capital Management's largest Q3 2018 buy was GSK: 291,168 shares worth $14.6M.
- Sio Capital Management added most to Alnylam Pharmaceuticals in Q3 2018, an estimated $7.48M increase.
- Sio Capital Management's biggest Q3 2018 reduction was Elevance Health, cutting an estimated $4.88M.
- Sio Capital Management fully exited Boston Scientific in Q3 2018, selling an estimated $5.97M.
- Sio Capital Management's ten largest holdings make up 41% of its $291M portfolio in Q3 2018.
- Sio Capital Management opened 36 new positions and closed 22 in Q3 2018.
- Sio Capital Management's portfolio value rose 61% quarter-over-quarter to $291M.
Based on Sio Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.